Saint-Gobain headquarters in the La Defense district of Paris. Photo: Nathan Laine/Bloomberg
Saint-Gobain Life Sciences has opened a new production facility in Dublin in a move that will create 30 to 40 new jobs over the next three years.
Saint-Gobain supplies manufacturing components to the life sciences sector.
The new facility, located in Citywest, will boost the company’s production in Ireland.
Saint-Gobain said the facility will also expand the company’s supply to both the life sciences and biopharmaceutical sectors in Ireland and overseas.
The business currently employs 80 people in Ireland, up from 19 six years ago. Saint-Gobain first entered the Irish market in 2018 through acquisition.
The number of employees here is expected to grow to between 110 and 120 people over the next three years if current growth trajectory continues.
This growth is driven by demand for essential components manufactured in a specialised cleanroom environment, Saint-Gobain reported.
The company’s products enable the production of drugs, including cancer and diabetes treatments, vaccines and orphan drugs for rare diseases, as well as Covid-19 and HIV therapies.
“This new production facility will enable us to expand our production capabilities for the supply of essential materials to the life sciences sector. In doing so, we will be able to continue the rapid expansion of our footprint in Ireland and create new employment opportunities at our state-of-the-art facility in Citywest,” chief executive Sung Yu said.
He added that Ireland is a global centre for the life sciences sector.
“Our company is a vital part of the supply chain for this key industry,” he said.
